Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Revenue (2022 - 2025)

Historic Revenue for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to $1.1 million.

  • InMed Pharmaceuticals' Revenue fell 1142.75% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.8 million, marking a year-over-year decrease of 327.37%. This contributed to the annual value of $4.9 million for FY2025, which is 750.16% up from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Revenue of $1.1 million as of Q3 2025, which was down 1142.75% from $1.3 million recorded in Q2 2025.
  • Over the past 5 years, InMed Pharmaceuticals' Revenue peaked at $2.3 million during Q2 2023, and registered a low of $265092.0 during Q4 2021.
  • Its 5-year average for Revenue is $992842.5, with a median of $1.1 million in 2024.
  • Per our database at Business Quant, InMed Pharmaceuticals' Revenue skyrocketed by 34896.15% in 2023 and then plummeted by 4448.16% in 2024.
  • InMed Pharmaceuticals' Revenue (Quarter) stood at $265092.0 in 2021, then soared by 77.22% to $469783.0 in 2022, then surged by 163.99% to $1.2 million in 2023, then decreased by 10.36% to $1.1 million in 2024, then rose by 0.76% to $1.1 million in 2025.
  • Its Revenue stands at $1.1 million for Q3 2025, versus $1.3 million for Q2 2025 and $1.3 million for Q1 2025.